Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis
Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.
FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months
The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.
Log in or Sign up for Free to view tailored content for your specialty!
Up-to-date HCC screening after HCV cure improves survival in patients with cirrhosis
Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.
Risk for heart, liver disease may vary between PCOS subtypes
Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.
Fazirsiran lowers serum, liver concentrations of Z-AAT in alpha-1 antitrypsin deficiency
In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.
‘Even one meal change’ to vegetarian, vegan can reduce serum ammonia in cirrhosis
Substitution of just one meat-based meal with a vegetarian or vegan alternative reduced serum ammonia levels for up to 3 hours and improved metabolites in patients with cirrhosis who follow a Western meat-based diet, researchers reported.
VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray
In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.
‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH
Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.
‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH
To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.
More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes
Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read